News and Trends 1 Mar 2019 Rapid Response mRNA Vaccine Facility Gets €30M Funding An mRNA vaccine facility, run by the German biotech CureVac, has received a €30M development grant to rapidly manufacture vaccines for regions hit by outbreaks of rabies, yellow fever and emerging diseases. CureVac is a company that develops vaccines made of mRNA, a molecule that lets cells translate genes into proteins. The company’s drug candidates […] March 1, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 1 Mar 2019 Update: Hansa Biopharma Applies for EMA Market Approval for Kidney Transplant Drug Update (01/03/2019): Hansa Biopharma (previously named Hansa Medical) has filed an application for marketing authorization for imlifidase with the EMA also for use in patients undergoing kidney transplants. Update (18/10/2018): Imlifidase has just been given Fast Track Designation by the FDA for application in transplantation. The designation should accelerate the treatment through the FDA’s regulatory process, with […] March 1, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 1 Mar 2019 This Biotech Uses Bacterial Proteins to Purify Water Faster Aquaporin is a company named after a protein that transports water molecules across a cell membrane. With these water channels, the Danish biotech is able to purify water 50% faster than conventional technology. Mission: To use water channel proteins to purify water in applications such as cleaning drinking water, desalination and industrial wastewater treatment. As […] March 1, 2019 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 28 Feb 2019 Austrian Biotech Raises €33.2M to Fund Cancer Vaccines A Series D round of €33.2M ($37.4M) is to help the biotech Hookipa advance the clinical development of therapeutic vaccines for virus-based cancers, as well as a prophylactic vaccine for cytomegalovirus, which can infect patients undergoing organ transplants. Currently at the preclinical stage, Hookipa’s therapeutic vaccines are designed to tackle cancers that are caused […] February 28, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 27 Feb 2019 UK Biotech Gets Huge Grant to Launch Off-the-Shelf CAR-T Cancer Therapy to Clinic The UK biotech Cell Medica has received a €7.6M ($8.7M) grant from the Cancer Prevention and Research Institute of Texas to advance an off-the-shelf CAR-T cell therapy that can work not only in blood cancer but also in solid tumors. The funding will help the company to develop a special type of CAR-T cell therapy […] February 27, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 27 Feb 2019 How to Make Cancer Drug Resistance Futile For many solid tumors, treatments undergo a cycle: the drugs initially work well, the tumor shrinks, but then becomes resistant again. Stefanie Flückiger-Mangual, CEO of the Swiss biotech Tolremo, believes that this cycle can be stopped. Solid tumors often act like a recurring villain in a TV series. Whatever drug you throw at them, however […] February 27, 2019 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 26 Feb 2019 Swiss Scientists Find ‘Silver Bullet’ Against Bacterial Infections Using the gene editing tool CRISPR-Cas9, researchers in Lausanne have uncovered antimicrobial molecules in the fruit fly that can selectively kill certain bacteria. This could lead to new therapeutics combatting antimicrobial resistance, and even preventing infections before they start. The research shows the antimicrobial molecules, or peptides, have the potential to treat infections of pathogens […] February 26, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 25 Feb 2019 Orchard Achieves Good Survival with Cell Therapy for Rare Immune Deficiency All 20 patients with a rare immunodeficiency disease survived for at least two years after receiving a cell therapy developed by Orchard Therapeutics. The patients had a genetic disease called adenosine deaminase–deficient severe combined immune deficiency (ADA-SCID) — also known as bubble boy syndrome. Caused by a mutation on a vital gene, the disease weakens […] February 25, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 22 Feb 2019 This Biotech’s Algorithm Accelerates Cell Therapy Development Mogrify is the new kid on the block for cell therapy. Based in Cambridge, UK, it boasts technology that could speed up the development of cell therapies by predicting the best chemical recipe to transform mature adult cells into other cell types. Mission: To use next-generation sequencing and gene expression data to develop more cost-effective […] February 22, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 22 Feb 2019 French Company to Open Biggest Insect Farm in the World A Series C round of €110M ($125M) — the largest ever for agriculture technology outside of the USA — will fund the construction of the world’s largest automated insect farm by the French company Ynsect. Ynsect is a company that uses insects to provide protein-rich feed for fish farming, pet food, and even the fertilizer industry. […] February 22, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 21 Feb 2019 First All-Inclusive Biotech Lab Facility Will Launch in Paris The young UK company RUNLABS plans to open the first facility where biotech companies can hire a package of lab space, lab services, offices, and even technicians. A common time sink in setting up a biotech company is the sheer amount of administration involved, such as hiring staff, getting insurance, and facilities maintenance. The company […] February 21, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 21 Feb 2019 Microbiome Biotech Will Use Series B to Bring Treatments to Clinic The Israeli biotech BiomX has raised €28M ($32M) to advance its treatments for acne and inflammatory bowel disease to the clinical stage. Investor interest is continuing in treatments based on the microbiome, which have the potential to treat a variety of conditions such as chronic inflammatory diseases, and even some forms of cancer. BiomX’s approach […] February 21, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email